Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New 9-Month pill regimen could transform Drug-Resistant TB care

NCT ID NCT07268664

First seen Jan 08, 2026 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests a 9-month, all-oral drug combination (BLMZ) for people with rifampicin-resistant tuberculosis. About 120 participants aged 12 and older will take the pills and be monitored for 24 months. The goal is to see if this shorter treatment works well and is safe for Chinese patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Center of Disease Prevention and Control in Kashi Area

    Kashgar, Xinjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hetian Prefecture Infectious Diseases Hospital

    Hetian, Xinjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third People's Hospital in Aksou

    Aksu, Xinjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.